Pauline R. Hoffman

TL;DR: Most convalescent plasma samples obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity, and rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.

TL;DR: Overall, the studies structurally define a recurrent anti-SARS-CoV-2 antibody class derived from VH3-53/Vh3-66 and similarity to a SARS- coV VH 3-30 antibody, providing criteria for evaluating vaccine-elicited antibodies.

TL;DR: In this article, a single immunization with mosaic RBD nanoparticles provides a potential strategy to simultaneously protect against SARS-CoV-2 and emerging zoonotic coronaviruses.

TL;DR: These studies structurally define a recurrent anti-SARS-CoV-2 antibody class derived from VH3-53/Vh3-66 and similarity to a SARS- coV VH 3-30 antibody, providing criteria for evaluating vaccine-elicited antibodies.

TL;DR: Rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.